{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:45:54Z","timestamp":1764510354618,"version":"build-2065373602"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T00:00:00Z","timestamp":1230681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alkylating agents form the basis of most combination treatment regimens for low\u2010grade lymphoproliferative disorders. Bendamustine is a unique alkylating agent that has distinctive preclinical activity in cell lines resistant to other alkylators. Furthermore, clinical activity has been demonstrated in patients with alkylating agent resistant disease. Recently, larger studies have been organized to study the clinical effects of bendamustine further. In indolent B\u2010cell non\u2010Hodgkin lymphoma that is resistant to rituximab, bendamustine induced a remission in 77% of patients. Myelosuppression was identified as the most common toxicity. In 2 studies of similar populations of patients, the combination of bendamustine and rituximab induced remission 90% of patients with a median progression\u2010free survival of 23\u201024 months. The overall remission rate was 59% in a prospective, randomized study of untreated patients with chronic lymphocytic leukemia, which was significantly greater than the rate of 26% in the chlorambucil control arm (<jats:italic>P<\/jats:italic> &lt; 0.001). Combined with rituximab, bendamustine induces a remission in 67% of patients with relapsed or refractory chronic lymphocytic leukemia. Bendamustine is an active agent for the treatment of low\u2010grade lymphoproliferative disorders and more study is needed to determine which dose and schedule is optimal, and which patients will derive the greatest benefit from its use. Cancer 2009. \u00a9 2008 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.24057","type":"journal-article","created":{"date-parts":[[2009,1,2]],"date-time":"2009-01-02T05:35:51Z","timestamp":1230874551000},"page":"473-479","source":"Crossref","is-referenced-by-count":31,"title":["Bendamustine"],"prefix":"10.1002","volume":"115","author":[{"given":"Matt","family":"Kalaycio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199606000-00007"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2787(72)90282-1"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"e_1_2_7_5_2","first-page":"278","article-title":"In vitro and ex vivo activity of SDX\u2010105 (bendamustine) in drug\u2010resistant lymphoma cells","volume":"2004","author":"Leoni LM","year":"2004","journal-title":"AACR Meeting Abstracts."},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-002-0331-8"},{"key":"e_1_2_7_7_2","first-page":"485","article-title":"In vitro induction of apoptosis of neoplastic cells in low\u2010grade non\u2010Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine","volume":"86","author":"Chow KU","year":"2001","journal-title":"Haematologica."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0050-z"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34877"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200110000-00003"},{"key":"e_1_2_7_11_2","first-page":"CD003805","article-title":"Chemotherapy plus rituximab versus chemotherapy alone for B\u2010cell non\u2010Hodgkin's lymphoma","volume":"4","author":"Schulz H","year":"2007","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_7_12_2","first-page":"39","article-title":"Treatment of follicular non\u2010Hodgkin's lymphoma","volume":"4","author":"Maloney DG","year":"2005","journal-title":"Curr Hematol Rep."},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_7_14_2","first-page":"1057","article-title":"SDX\u2010105 (bendamustine) inhibits growth of SU\u2010DHL\u20101 and Daudi lymphoma xenografts in SCID mice","volume":"2004","author":"Kanekal S","year":"2004","journal-title":"AACR Meeting Abstracts."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34873"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_7_18_2","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL study group","volume":"90","author":"Bergmann MA","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_7_19_2","first-page":"2043","article-title":"Bendamustine versus chlorambucil in treatment\u2010naive patients with B\u2010cell chronic lymphocytic leukemia (B\u2010CLL): results of an international phase III study","volume":"110","author":"Knauf WU","year":"2007","journal-title":"ASH Annual Meeting Abstracts."},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61125-8"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2395"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0762"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1385\/1592593836"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_7_27_2","first-page":"3106","article-title":"Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG)","volume":"110","author":"Fischer K","year":"2007","journal-title":"ASH Annual Meeting Abstracts."},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000123546"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400004521"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34876"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24057","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:10:51Z","timestamp":1760299851000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24057"}},"subtitle":["A new look at an old drug"],"short-title":[],"issued":{"date-parts":[[2009,1,20]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1002\/cncr.24057"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24057","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2009,1,20]]}}}